113 results
10-K
2023 FY
EX-10.6
INTI
Inhibitor Therapeutics, Inc.
Annual report
29 Mar 24
4:05pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
18 Oct 23
Departure of Directors or Certain Officers
9:54am
8-K
EX-10.3
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.2
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.4
u584y2sfbg8iv399 gu
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
a0b xeneavkbxllh
18 Jan 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
0pb5138k3i
17 Dec 20
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
24let gafgc
6 May 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-10.1
12npv mhwrpz3q
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.2
yrgh8ews9 x92
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.1
p7342zm 0oi
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am
8-K
EX-10.2
qi3lx9wsqx2 w9pd
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am